(News Bulletin 247) – Oddo BHF reaffirms its ‘underperformance’ opinion and its price target of 265 Swiss francs on Roche, the day after the publication of interim results deemed ‘half-hearted and inconclusive at this stage’ for the phase III SKYSCRAPER-01 study.
The design office declares that it remains cautious pending the final analysis of OS (overall survival) for this study evaluating the combination of tiragolumab and Tecentriq in metastatic non-small cell lung cancer.
“Beyond the gloomy financial outlook in 2023, we anticipate rather poor clinical newsflow in the medium term with the exception of the OS results from SKYSCRAPER-01 which could be a significant inflection point for the stock”, asserts the ‘analyst.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
